Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD Royalty expense

Royalty expense at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
——

Segments

By segment

See full
Reportable Segment Aggregation Before Other Operating$13.13M+17.4%

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×